FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

類似資料

• FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
  著者:: Odogwu, Lauretta, 等
  出版事項: (2018)
• FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
  著者:: Sul, Joohee, 等
  出版事項: (2016)
• FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
  著者:: Larkins, Erin, 等
  出版事項: (2017)
• FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
  著者:: Kazandjian, Dickran, 等
  出版事項: (2016)
• Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs
  著者:: Kim, Janice, 等
  出版事項: (2019)